Preview
  • Drugs and the FDA

  • Safety, Efficacy, and the Public's Trust
  • By: Mikkael A. Sekeres
  • Narrated by: Mike Lenz
  • Length: 8 hrs and 40 mins
  • 4.7 out of 5 stars (6 ratings)

Prime logo Prime members: New to Audible?
Get 2 free audiobooks during trial.
Pick 1 audiobook a month from our unmatched collection.
Listen all you want to thousands of included audiobooks, Originals, and podcasts.
Access exclusive sales and deals.
Premium Plus auto-renews for $14.95/mo after 30 days. Cancel anytime.

Drugs and the FDA

By: Mikkael A. Sekeres
Narrated by: Mike Lenz
Try for $0.00

$14.95/month after 30 days. Cancel anytime.

Buy for $21.49

Buy for $21.49

Pay using card ending in
By confirming your purchase, you agree to Audible's Conditions of Use and Amazon's Privacy Notice. Taxes where applicable.

Publisher's summary

Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer's drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate United States authority on a drug's safety and efficacy? In Drugs and the FDA, Mikkael Sekeres—a leading oncologist and former chair of the FDA's cancer drug advisory committee—tells the story of how the FDA became the most trusted regulatory agency in the world. It took a series of tragedies and health crises, as well as patient advocacy, for the government to take responsibility for ensuring the efficacy and safety of drugs and medical devices.

Before the FDA existed, drug makers could hawk any potion, claim treatment of any ailment, and make any promise on a label. But then, throughout the twentieth century, the government was forced to take action when children were poisoned by contaminated diphtheria and smallpox vaccines, an early antibiotic contained antifreeze, a drug prescribed for morning sickness in pregnancy caused babies to be born disfigured, and access to AIDS drugs was limited to a few clinical trials while thousands died. Sekeres describes all these events against the backdrop of the contentious 2011 hearings on the breast cancer drug Avastin, in which he participated as a panel member.

©2022 Mikkael A. Sekeres (P)2023 Tantor
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Drugs and the FDA

Average customer ratings
Overall
  • 4.5 out of 5 stars
  • 5 Stars
    4
  • 4 Stars
    2
  • 3 Stars
    0
  • 2 Stars
    0
  • 1 Stars
    0
Performance
  • 3.5 out of 5 stars
  • 5 Stars
    2
  • 4 Stars
    1
  • 3 Stars
    1
  • 2 Stars
    1
  • 1 Stars
    1
Story
  • 4.5 out of 5 stars
  • 5 Stars
    3
  • 4 Stars
    3
  • 3 Stars
    0
  • 2 Stars
    0
  • 1 Stars
    0

Reviews - Please select the tabs below to change the source of reviews.

Sort by:
Filter by:
  • Overall
    4 out of 5 stars
  • Performance
    1 out of 5 stars
  • Story
    4 out of 5 stars

Metastic

As a cancer doc interested in drug development the book has good content and narrative. Why can’t the reader pronounce METASTATIC in a book like this and keep saying METASTIC

Good lord - where is the editing on something so simple and central to the book

Something went wrong. Please try again in a few minutes.

You voted on this review!

You reported this review!

1 person found this helpful

  • Overall
    4 out of 5 stars
  • Performance
    2 out of 5 stars
  • Story
    5 out of 5 stars

What is “metastic”?

Very good overview of fda drug approval, but the reader says “metastic” instead of metastatic. Metastic is not a word.

Something went wrong. Please try again in a few minutes.

You voted on this review!

You reported this review!

  • Overall
    5 out of 5 stars
  • Performance
    3 out of 5 stars
  • Story
    5 out of 5 stars

Great book but reading of professional word needs improve

It is a Great book but reading of professional word needs improvement such as ‘metastatic’.

Something went wrong. Please try again in a few minutes.

You voted on this review!

You reported this review!